ZyVersa Therapeutics, Inc. ZVSA

ZVSA Company Overview

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and renal diseases with significant unmet medical need. The company operates within the biotechnology and specialty therapeutics industries and concentrates on leveraging anti-inflammatory and immune-modulating approaches to address chronic degenerative conditions. ZyVersa’s primary programs have centered on inflammasome inhibition and renal disease therapeutics, with its pipeline historically including candidates targeting kidney disorders and inflammatory pathways associated with fibrosis and immune dysregulation.

The company’s core value proposition is its focus on targeting the NLRP3 inflammasome pathway, which has been implicated in multiple inflammatory and fibrotic diseases. ZyVersa has positioned itself as an emerging specialty biotech company seeking to develop differentiated therapies in areas where current treatment options remain limited or largely symptomatic. The company traces its origins to a strategy of acquiring and advancing clinical-stage assets in nephrology and inflammatory disease, evolving into a publicly traded biotechnology company listed on Nasdaq under the ticker ZVSA following corporate restructuring and financing activities.